Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2022-07-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
第十届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 10th Board of Directors of Changchun High-tech Industry (Group) Co., Ltd. It includes voting results on various proposals related to the company's 2022 restricted stock and stock option incentive plan, authorization for the board to handle related matters, and the scheduling of the company's 2022 first extraordinary general meeting. The document is focused on board decisions and governance matters, specifically about stock incentive plans and shareholder meeting arrangements. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results declaration but rather a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters and contains substantive content about board decisions, not just a brief announcement or a certification, so it is not RPA or RNS.
2022-07-08 Chinese
长春高新技术产业（集团）股份有限公司2022年限制性股票与股票期权激励计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of a 2022 restricted stock and stock option incentive plan by Changchun High-tech Industry (Group) Co., Ltd. It extensively discusses the plan's purpose, management, scope, stock sources, quantities, pricing, conditions, and legal compliance. The content is focused on equity incentive plans, stock options, and related governance and regulatory compliance. It is not a financial report, earnings release, or regulatory filing per se, but a comprehensive disclosure of a stock incentive plan draft. This type of document aligns with announcements or detailed disclosures related to capital structure changes and equity incentive plans. According to the filing definitions, such documents fall under Capital/Financing Update (CAP) because they provide updates on company financing activities and capital structure changes, specifically stock-based compensation plans. The document length and detail confirm it is the plan itself, not just an announcement of a report, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2022-07-08 Chinese
长春高新技术产业（集团）股份有限公司2022年限制性股票与股票期权激励计划管理办法
Governance Information Classification · 95% confidence The document is a detailed management method for a 2022 restricted stock and stock option incentive plan of Changchun High-tech Industry (Group) Co., Ltd. It includes legal references, approval procedures, implementation steps, accounting treatments, and disclosure obligations related to the stock incentive plan. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for the company's stock incentive plan, including board and shareholder approvals, legal opinions, and accounting policies. Therefore, it fits best under Governance Information (CGR). The document length (8818 characters) and content confirm it is a full governance policy document, not a brief announcement or regulatory filing.
2022-07-08 Chinese
关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting (临时股东大会) of Changchun High-tech Industry (Group) Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, and proxy voting instructions. The content is focused on the announcement and procedural details for the shareholders' meeting rather than the results or materials presented at the meeting. The document length is 4198 characters, which is relatively short and consistent with a meeting notice rather than a full report or voting results. There is no indication that this is a report of voting results or a proxy solicitation document. Therefore, the document best fits the category of a shareholder meeting notice, which aligns with the AGM Information (AGM-R) category as it is about the Annual or Extraordinary General Meeting information and materials shared for the meeting.
2022-07-08 Chinese
关于控股子公司重组人生长激素注射液新适应症获得《药品注册证书》的公告
Regulatory Filings Classification · 100% confidence The document is a public announcement by a company regarding the approval of an additional indication for a pharmaceutical product by the national drug regulatory authority. It contains no financial data, no mention of financial results, no management or board changes, no voting results, no legal proceedings, no capital or financing updates, and no report attachments. The document is short (712 characters) and is an official regulatory announcement about product registration approval. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-06 Chinese
关于控股子公司注射用金纳单抗获得美国FDA药物临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the approval by the US FDA for clinical trials of a drug by a subsidiary of the company. It contains no financial data, no detailed report, and is primarily an official notification of a regulatory milestone related to drug clinical trial approval. The document length is only 626 characters, indicating it is a brief announcement rather than a full report. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not related to management changes, voting results, or capital changes. The content is regulatory in nature, announcing FDA approval for clinical trials, which is a regulatory event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-06-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.